OrbiMed’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

OrbiMed’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-835,842	Closed	-$5.4M	–	149
2019 Q3	$5.4M	Hold	835,842	–	–	0.1%	92
2019 Q2	$10.3M	Hold	835,842	–	–	0.16%	93
2019 Q1	$11.3M	Hold	835,842	–	–	0.18%	87
2018 Q4	$3.35M	Hold	835,842	–	–	0.06%	111
2018 Q3	$5.63M	Buy	+835,842	New	+$7.96M	0.07%	126

Other funds holding CNST

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ROTUOC

Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

OrbiMed's CNST Position: Q4 2019 in Review

OrbiMed sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q4 2019, closing a stake of 835,842 shares — an estimated $5.4M sold.

OrbiMed first reported a position in CNST in Q3 2018 and held it in 5 quarters. The position peaked at $11.3M in Q1 2019. 100 funds tracked by Wall St. Rank hold CNST as of Q4 2019.

OrbiMed reported no remaining Constellation Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
OrbiMed sold 835,842 Constellation Pharmaceuticals, Inc. shares in Q4 2019, an estimated $5.4M.
OrbiMed first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 5 quarters.
OrbiMed's Constellation Pharmaceuticals, Inc. position peaked at $11.3M in Q1 2019.
100 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q4 2019.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.